Overview

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with persistent or recurrent endometrial carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Alessandro Santin
Collaborators:
Gilead Sciences
Immunomedics, Inc.
Treatments:
Camptothecin
Immunoconjugates